

SCIENCE

Published by the **American Association for the Advancement of Science (AAAS)**, *Science* serves its readers as a forum for the presentation and discussion of important issues related to the advancement of science, including the presentation of minority or conflicting points of view, rather than by publishing only material on which a consensus has been reached. Accordingly, all articles published in *Science*—including editorials, news and comment, and book reviews—are signed and reflect the individual views of the authors and not official points of view adopted by the AAAS or the institutions with which the authors are affiliated.

Membership/Circulation

Director: Michael Spinella

Fulfillment: Marlene Zendell, *Manager*; Gwen Huddle, *Assistant Manager*; Mary Curry, *Member Service Supervisor*; Pat Butler, Helen Williams, Laurie Baker, *Member Service Representatives*

Promotions: Dee Valencia, *Manager*; Hilary Baar, Angela Mumeka, *Coordinators*

Research: Kathleen Markey, *Manager*; Robert Smariga, *Assistant*

Financial Analyst: Jacquelyn Roberts

Administrative Assistant: Nina Araujo de Kobes
Science Member Services

Marion, Ohio: 800-347-6969;

Washington, DC: 202-326-6417

Advertising and Finance

Associate Publisher: Beth Rosner

Advertising Sales Manager: Susan A. Meredith

Recruitment Advertising Manager: Janis Crowley

Advertising Business Manager: Deborah Rivera-Wienhold

Financial Manager: Leslie Gelder

Marketing Manager: Laurie Hallowell

Traffic Manager: Tina Turano

Recruitment: Michele Pearl, *Operations Manager*;

Dan Moran, *Traffic Manager*; Debbie Cummings,

Millie Muñoz-Cumming, Angela Wheeler, *Sales*

Marketing Associate: Allison Pritchard

Reprints Manager: Corrine Harris

Permissions Manager: Arlene Ennis

Sales Associate: Carol Maddox

ADVERTISING SALES: East Coast/E. Canada:

Richard Teeling, 201-904-9774, FAX 201-904-9701 •

Southeast: Mark Anderson, 305-856-8567, FAX 305-

856-1056 • **Midwest:** Donald Holbrook, 708-516-

8882, FAX 708-516-8883 • **West Coast/W. Canada:**

Neil Boylan, 415-673-9265, FAX 415-673-9267 • **UK,**

Scandinavia, France, Italy, Belgium, the Netherlands:

Andrew Davies, (44) 457-838-519, FAX (44)

457-838-898 • **Germany/Switzerland/Austria:**

Tracey Peers, (44) 270-760-108, FAX (44) 270-759-

597 • **Japan:** Mashy Yoshikawa, (3) 3235-5961, FAX

(3) 3235-5852

Recruitment: 202-326-6555, FAX 202-682-0816

European Recruitment: AnneMarie Vis, (44) 0223-

302067, FAX (44) 0223-302068

Send materials to *Science* Advertising, 1333 H Street,

NW, Washington, DC 20005.

Information for Contributors appears on pages 40–42 of the 1 January 1993 issue. Editorial correspondence, including requests for permission to reprint and reprint orders, should be sent to 1333 H Street, NW, Washington, DC 20005. **Science Telephone:** 202-326-6500, TDD 202-408-7770. **Other AAAS Programs:** 202-326-6400.

LETTERS

HIV and AIDS

The article “Keystone’s blunt message: ‘It’s the virus, stupid’ ” by Jon Cohen (News, 16 Apr., p. 292) describes the state of the art of AIDS research, but also the state of the minds of AIDS researchers (1). Cohen writes that to AIDS researchers it is either a “conundrum,” or “many puzzles,” or a “disparity” that “the immune system collapses despite . . . only minute amounts of HIV” Yet they reject an alternative explanation as an “anti-HIV hypothesis” and dissidents with the slogan “It’s the virus, stupid.” Is a non-HIV-AIDS hypothesis stupid because it is an anti-HIV hypothesis?

The drug-AIDS hypothesis I have proposed is not a puzzle. It predicts AIDS after individuals inject themselves with psychoactive street drugs (as more than 80,000 American AIDS patients have done) and after they inhale mutagenic and toxic nitrates (as many male homosexual AIDS patients have done) for the 10 years that it is said that HIV requires to cause AIDS (1). It also predicts immunodeficiency from the killing of the highly proliferative cells of bone marrow with the DNA chain terminator AZT (2), which is currently prescribed to more than 200,000 HIV-positive people with and without AIDS (1).

Indeed, the recent summit of HIV trackers that Cohen reviews has provided the best alibi yet for HIV: “Using creative new techniques . . . that are much more sensitive than previous methods, several scientists have found that there is far more HIV in infected people than was previously thought.” For example, “quantitative competitive PCR” (polymerase chain reaction) analysis was shown by George Shaw and his colleagues (M. Piatek, Jr., *et al.*, Reports, 19 Mar., p. 1749) “to be as much as 60,000 times more sensitive than culture-based plasma viremia assays at detecting HIV in plasma.” But does it help the emperor to wear clothes that can only be seen with “creative new techniques”?

In my view, Shaw and his colleagues virtually prove, with an impressive and exhaustive collection of new data, that HIV is not the cause of AIDS. (i) During the primary infection, before immunity, there are 10^3 to 10^4 infectious HIVs and 3×10^5 to 2×10^7 HIV RNAs per milliliter of plasma. Thus the new technique sees indeed 10^3 to 10^5 times more RNA than infectious HIV. But there is no AIDS, and the T cell counts are normal. (ii) After

immunity, there are no infectious HIVs and about 10^3 to 5×10^5 HIV RNAs per milliliter of plasma. There is also no AIDS, and the T cell counts are normal or almost normal. (iii) Once immunodeficiency is acquired and AIDS appears, there are no infectious HIVs per milliliter in 5 out of 27 cases, fewer than 25 in 6 out of 27 cases, and 10^2 to 10^5 in 16 out of 27 cases. HIV RNAs range from 3.6×10^4 to 9×10^6 per milliliter, despite the complete absence of T cells, the presumed source of HIV, in several HIV RNA-millionaires! The fluctuation of infectious HIV from 0 to 10^5 in otherwise identical AIDS patients indicates to me that HIV is not the cause of AIDS, but instead an optional opportunist of immunodeficiency.

If HIV were the cause of AIDS, T cells would drop and AIDS would appear during the primary infection, when HIV titers are high and there is no antiviral immunity. But if it were an opportunist of an immunodeficiency induced by another cause such as drugs, its titer might be either high or low or zero, exactly as Shaw and his colleagues report. Thus HIV appears to be just another AIDS opportunist like *Pneumocystis carinii*, candida, cytomegalovirus, and so forth. Sound stupid? And are the more than 3000 documented HIV-free AIDS cases (1) stupid too?

Peter Duesberg

Department of Molecular and Cell Biology,
University of California,
Berkeley, CA 94720

References

1. P. H. Duesberg, *Pharmacol. Therapeut.* 55, 201 (1992).
2. G. Kolata, *Science* 235, 1462 (1987); N. Mir and C. Costello, *Lancet* ii, 1195 (1988).

Response: Duesberg’s views on the pathogenesis of AIDS (1), responses to his hypothesis from other investigators (2), and comments on the rhetorical approaches Duesberg has employed in presenting his views (3) have been sufficiently documented in the literature to preclude the need for recapitulation here. Suffice to say that, in contrast to the interpretation offered by Duesberg, we believe our results, along with the data presented in recent publications by Pantaleo *et al.* (4) and Embretson *et al.* (5), in combination with an extensive body of clinical, epidemiological, and laboratory data accumulated over the past 12 years [reviewed in (6)], are

**Monoclonal Antibodies
to Human Leukocyte
Cell Surface Molecules**



Acell™

For Antigen Presentation Research

800-374-9523

FAX: 612-439-1940 Phone: 612-439-0835

Acell Corporation P.O.Box 87 Bayport Minnesota 55003-0087

Circle No. 37 on Readers' Service Card

1993 AAAS Philip Hauge Abelson Prize Nominations Invited

The AAAS Philip Hauge Abelson Prize, established by the AAAS Board of Directors in 1985, is awarded annually either to:

- **a public servant**, in recognition of sustained exceptional contributions to advancing science, or

- **a scientist** whose career has been distinguished both for scientific achievement and for other notable services to the scientific community.

AAAS members are invited to submit nominations now for the 1993 prize, to be awarded at the 1994 Annual Meeting in San Francisco.

Each nomination must be seconded by at least two other AAAS members.

Nominations should be typed and should include the following information: the nominator's name, address, and phone number; the nominee's name, title, address, and brief biographical résumé (please do not send lengthy publication lists); statement of justification for the nomination; and names, identification, and signatures of the three or more AAAS member sponsors.

The winner will be selected by a seven-member selection panel. The Prize consists of a plaque and \$2500. The award recipient is reimbursed for travel and hotel expenses incurred in attending the award presentation.

Nominations should be submitted to Stephen D. Nelson, Directorate for Science and Policy Programs, AAAS, 1333 H Street, NW, Washington, DC 20005, for receipt by **1 August 1993**.

consistent with a central role for HIV-1 in the pathogenesis of AIDS. While Duesberg is entitled to his opinions, we share neither his views on the pathogenesis of AIDS nor his interpretation of our results.

Jeffrey D. Lifson
Michael Piatak, Jr.
Genelabs Technologies, Inc.,
505 Penobscot Drive,
Redwood City, CA 94063
Michael S. Saag
George M. Shaw
University of Alabama,
Birmingham, AL 35294

References

1. P. H. Duesberg, *Proc. Natl. Acad. Sci. U.S.A.* **86**, 755 (1989); *ibid.* **88**, 1575 (1991); *Lancet* **341**, 957 (1993); *Science* **242**, 997 (1988); *Pharmacol. Ther.* **55**, 201 (1992).
2. A. R. Moss, D. Osmond, P. Bacchetti, *Science* **242**, 997 (1988); M. S. Ascher *et al.*, *Nature* **362**, 103 (1993); M. T. Schechter *et al.*, *Lancet* **341**, 658 (1993).
3. J. Maddox, *Nature* **363**, 109 (1993).
4. G. Pantaleo *et al.*, *ibid.* **362**, 355 (1993).
5. J. Embretson *et al.*, *ibid.*, p. 359.
6. G. Pantaleo *et al.*, *N. Engl. J. Med.* **328**, 327 (1993).

There is no question that people infected with HIV will eventually develop AIDS, and one should take every precaution to avoid becoming infected. There is also no doubt that we could cure AIDS if we could eliminate HIV from the body of infected individuals. Unfortunately, this is an unrealistic goal. In order to develop more effective AIDS treatments that might induce remission, we need to pay more attention to the human immune system, and not just the virus. As in the many other mammalian diseases associated with retroviruses, the immune system itself is partly to blame for AIDS. In this sense, the political slogan, "It's the virus, stupid," may be counterproductive.

In a recent clinical trial of an experimental AIDS vaccine (1), we found a statistically significant negative correlation between the proliferation of CD8-type lymphocytes and the survival of CD4-type lymphocytes. An increase in CD8 cells and a decrease in CD4 cells are both characteristic of AIDS, and the latter leads to the immune deficiency that characterizes the disease. By "correlation," we do not just mean that CD8 cells increased as CD4 cells decreased. If it were that simple, both phenomena could be independent effects of HIV infection. We also mean that a vaccine used to reduce CD8 cells caused a rebound in CD4 cells. This would not be possible if the virus were the whole story.

Perhaps a more compelling example is the response of an HIV patient who was injected with a test dose of monoclonal antibodies that produced a marked decrease

in the patient's suppressor CD8 cells (2). Within 3 days, the patient's CD4 cells had rebounded into the normal range, with the CD4 percentage rising from 15 to 36%. Although the effect of one dose was short-lived, it underscores the important role of the immune system in the destruction of CD4 cells and the fallacy of focusing on the virus alone.

Readers interested in the mechanisms by which HIV-stimulated CD8 cells kill CD4 cells may refer to the work of Zarling *et al.* (3). The main point is that restricting attention to HIV may preclude the development of promising therapeutic approaches, such as those outlined above.

Allen D. Allen
Glenn E. Mathisen
Norman Glover
Janet Au

Olive View-UCLA Medical Center,
Sylmar, CA 91342-1495

References

1. A. D. Allen, G. E. Mathisen, N. Glover, J. Au, *AIDS*, in press.
2. W. Leader, personal communication.
3. J. M. Zarling *et al.*, *J. Immunol.* **144**, 2992 (1990).

During the past decade, several investigators not mentioned by Cohen have emphasized the role of the lymphoid organs as a reservoir for HIV-1, especially the group of Paul R  cz and Klara Tenner-R  cz in Hamburg, Germany. These investigators put the presence of HIV-1 particles and proteins in the germinal centers into the broader perspective of the physiological function of these anatomical sites (1). They emphasized the follicular dendritic cells (FDCs), which form an intricate network of dendrites in close contact with B cells, and which are the pivotal antigen-presenting cells in the generation and maintenance of B cell memory because they retain immune complexes. Embretson *et al.* (2) extended this work, using advanced polymerase chain reaction techniques, and several other European and American groups, using similar histopathological approaches, made early crucial contributions [cited in (1)].

The finding that CD8-positive cells infiltrate germinal centers during the development of AIDS, including detailed quantitation of CD8 cells in the germinal centers (3), has been described extensively in these earlier studies. However, clear hypotheses about the role and function of these cells were scarce. Therefore, my colleagues and I postulated that they are involved in cytotoxic activity directed against the FDC network (4). This network progressively degenerates and eventually disappears over the course of HIV-1 infection and the development of AIDS, which leads to the loss of lymphoid architecture and to

Mean calculations don't have to be so consuming.



No matter how you look at it, data analysis can be a real monster.

That's why GraphPad is pleased to introduce **InStat** and **InPlot**, powerful and easy-to-use scientific software that can really take a bite out of your workload.

InStat. Instant Biostatistics.

Unlike heavy-duty programs designed for statisticians, **InStat** is designed for *scientists*. Even if your knowledge of statistics is a bit rusty, **InStat**'s clear language makes it easy to calculate *t* tests, nonparametric tests, one-way ANOVA, chi-square, Fisher's test, linear regression and needed sample size. Not sure which test to use? Simply use the built-in help screens.

InPlot. Scientific Graphics.

InPlot makes it equally easy to quickly analyze your raw data and create polished graphs – complete with error bars, log axes and scientific symbols. Curve fitting with nonlinear regression has never been easier. There are even special features for radiogland binding and RIAs. And **InPlot** is so easy-to-learn, you can create your first graph in minutes.

Both programs are backed by an unconditional, 90-day guarantee and free technical support.*

Call (800) 388-4723 today for more information. Because analyzing data no longer has to be like pulling teeth.

GraphPad™

Intuitive software for science.

10855 Sorrento Valley Road, Suite 203 • San Diego, CA 92121 • USA
TEL. (800) 388-4723, (619) 457-3909 • FAX (619) 457-8141

*InPlot costs \$395 and is a DOS program. InStat costs \$95 and is available in DOS and MAC versions.

LASERGENE BY DNASTAR

comprehensive software for molecular biology



Network Version



Gives power and flexibility to every lab on your site!

LASERGENE access for every researcher

Unrestricted network geography

Only the server installs or updates

... superior software systems

DNA & Protein Sequence Analysis. Multiple Alignment. Databases.
Restriction Sites & Maps. Sequencing (with automated, semi-automated or manual)
all run simultaneously on a LASERGENE network

DNASTAR

Call DNASTAR today and optimise
your current hardware and personnel
with a LASERGENE Network

USA: tel (608) 258 7420 fax (608) 258 7439
Europe: tel (UK44) 081 566 8282 fax (UK44) 081 566 9555

Circle No. 30 on Readers' Service Card

The Procter & Gamble Company International Program for Animal Alternatives

A Call for Research Proposals

The Procter & Gamble Company is committed to the development and use of new methods for testing the efficacy and safety of drugs and consumer products that eliminate or reduce the use of animals or distress imposed on animals. The International Program for Animal Alternatives will provide funds for research to develop such methods.

Funding: Up to \$50,000 annually for up to 3 years. Three such grants will be awarded.

Deadline for Application: September 1.

Announcement of Recipients: January 1.

Proposals will be accepted from any academic or non-profit medical research institution. The Company is interested in proposals in the following areas:

Efficacy Testing

- Inflammation/Arthritis
- Diseases of the Oral Cavity
- Nutritional and Gastrointestinal Disorders
- Cardiovascular Disorders
- Bone Disorders
- Skin Disorders
- Respiratory Diseases
- Rational Drug Design
- Structure - Activity Relationships

Safety Testing

- Ocular Irritation
- Acute Oral Toxicity
- Skin Irritation
- Contact Sensitization
- Developmental Toxicity
- Respiratory Toxicity
- Neurotoxicity
- Computer Modeling of Toxicologic Processes
- Structure - Activity Relationships

Enquiries and requests for applications should be directed to:

Program Administrator
International Program for Animal Alternatives
The Procter & Gamble Company
Miami Valley Laboratories
P.O. Box 398707
Cincinnati, Ohio 45239-8707
Fax (513) 627-1153

dramatically altered immune responsiveness (1). It is possible that the immune complexes which are retained on the membrane of FDCs by Fc- and C3b-receptors during the physiological process of B memory cell formation serve as a target for CD8-positive cytotoxic T cells (4). The abundance of HIV-1 particles and of immune complexes containing HIV-1 antigens in the germinal center may promote access of CD8⁺ cells to this anatomical site, where these cells are not found in control lymph nodes. Some HIV-1 antigens mimic self-proteins and may provoke autoimmune-like reactions. In addition, the CD8⁺ cells in the lymphoid follicle may belong to the population of CD8⁺ cells (4) that secrete a soluble factor which inhibits HIV-1 replication (5).

Jon D. Laman

Department of Immunology and
Medical Microbiology,
Medical Biological Laboratory TNO,
2280 HV Rijswijk,
The Netherlands

References

1. P. Rácz *et al.*, *Prog. Allergy* **37**, 81 (1986).
2. J. Embretson *et al.*, *Nature* **362**, 359 (1993).
3. G. S. Wood, B. F. Burns, R. F. Dorfman, R. A. Warnke, *Blood* **67**, 596 (1986); S. Brask, *Acta Pathol. Microbiol. Immunol. Scand.* **95**, 155 (1987).
4. J. D. Laman, E. Claassen, E. Van Rooijen, W. J. A. Boersma, *AIDS* **3**, 543 (1989); J. D. Laman and A. J. M. Van den Eertwegh, *ibid.* **6**, 333 (1992).
5. C. M. Walker, D. J. Moody, D. P. Stites, J. A. Levy, *Science* **234**, 1563 (1986).

Sorry, Doctor

I was appalled to learn of the new layers of bureaucracy established at the National Institutes of Health (NIH) for controversial proposals (News & Comment, 26 Mar., p. 1820). The establishment of the protocol implementation review committees (PIRCs) and a second-tier "panel to review the research further" has significant, adverse consequences for many clinical and basic researchers. Doesn't the premier research institution in the world know that research, by definition, is controversial?

Just think of the potential "good" such a bureaucracy could serve. Fetal tissue research? Nope, can't fund it. Too controversial. Research about children's knowledge about sex and birth control? Nope, can't fund it. Has offensive language in the questionnaire and it's too controversial. Racial violence research? Nope, can't fund it. Might upset certain minority groups. Animal research? Nope, can't fund it. The animal rights lobby is too strong. Besides, it's too controversial. Cochlear implants for deaf infants and children? Nope, can't fund it. A few deaf advocacy groups think that